// App-Quantinova.ai

2987 : Generation of a selectively cytotoxic fusion protein against p53 mutated cancers

Researchers

Presenter

  • Agamemnon A. Epenetos

Principal Investigators

  • Christina Kousparou

  • Aleksandra Filipovic

Medical Centers

  • Trojantec Ltd, London, United Kingdom

  • Imperial College, London, United Kingdom

Locations

  • United Kingdom

Companies

  • Trojantec ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • p53

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved